A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Last updated: January 28, 2025
Sponsor: Almirall, S.A.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Scalp Disorders

Psoriasis And Psoriatic Disorders

Warts

Treatment

Tildrakizumab

Clinical Study ID

NCT06030076
SW-ATCH
  • Ages > 18
  • All Genders

Study Summary

The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Written informed consent.

  2. >=18 years of age.

  3. Moderate-to-severe plaque psoriasis currently treated with a biologic therapy (TNFαantagonist, IL12/23 antagonist, IL17 antagonist).

  4. Switch to tildrakizumab due to:

  5. primary or secondary treatment failure (PASI >= 3 or ΔPASI < 75 and/or DLQI >

  1. adverse events, contraindication, intolerance

  2. patient wish (dosing regimen), lack of adherence, or other, includingnonmedical reason

  3. Treatment with tildrakizumab planned in the frame of clinical practice.

Exclusion

Exclusion Criteria:

  1. Patient appears to be unwilling or unable to comply with the requirements of thestudy or who, in the opinion of the Investigator, should not participate in thestudy.

  2. >=3 previous biologic treatments in the last 3 years.

  3. Participation in a clinical trial simultaneous to participation in SW-ATCH.

  4. Any condition preventing prescription of Tildrakizumab according to the SmPC,including but not restricted to any contraindication or history of hypersensitivityor intolerance.

  5. Patient dependent on the Investigator.

  6. Previous treatment with Tildrakizumab.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Tildrakizumab
Phase:
Study Start date:
September 06, 2023
Estimated Completion Date:
October 31, 2025

Connect with a study center

  • Gesundheitszentrum Citypark Graz

    Graz, Styria 8010
    Austria

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.